Company Overview
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.14.
Recent Developments
- Dec 2025 Revenue of $1.93M (-79.2% YoY); net profit $-10.49M.
- Trailing 12 Months Year-on-year growth — revenue -78.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -25.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -25.10% |
| 1 Year: | -78.70% |
Stock Price Performance
| 1 Year: | -96.57% |
| 6 Months: | -82.64% |
| 3 Months: | -46.10% |
| 1 Month: | -28.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -25.1% CAGR over 5 years.
- Trading 98.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ISPC iSpecimen Inc. PHARMA | 1.59 | -0.03 | $4.00M | 0.00% | - | - | -25.10% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 1.50M | 2.25M | 2.96M | 2.90M | 2.72M | 2.52M | 2.34M | 2.58M | 2.95M | 1.63M | 2.78M | 2.29M | 2.86M | 2.66M | - | - | - | - |
| Operating Income | - | -305.01K | -723.08K | -942.64K | -1.53M | -1.46M | -2.36M | -2.59M | -3.10M | -2.54M | -3.56M | -2.19M | -3.00M | -2.18M | -1.71M | -1.64M | -1.82M | -2.83M | -2.54M |
| Net Income | -1.64M | -174.09K | -1.25M | -3.96M | -1.39M | -1.55M | -2.38M | -2.61M | -3.10M | -2.43M | -3.48M | -2.11M | -2.90M | -2.11M | -1.44M | -1.66M | -1.05M | -2.78M | -2.28M |
| Diluted EPS | - | - | - | -4.23 | -0.87 | -0.22 | -0.27 | -0.30 | -0.35 | -0.27 | -0.39 | -4.66 | -6.36 | -3.72 | -2.10 | -28.55 | -0.42 | -0.48 | -6.66 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 8.18M | 11.14M | 10.40M | 9.93M | 9.29M | 1.93M |
| Operating Income | -2.41M | -5.93M | -10.19M | -11.17M | -12.73M | -8.98M |
| Net Income | -4.65M | -8.96M | -10.25M | -11.10M | -12.50M | -10.49M |
| Diluted EPS | -4.97 | -2.09 | -1.16 | -24.55 | -17.58 | -2.28 |
| R&D Expense | 319.24K | 879.24K | 1.47M | 1.62M | 1.49M | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 6.21M | 35.72M | 24.62M | 15.82M | 9.35M | 9.53M |
| Total Equity | -22.72M | -27.28M | 29.79M | 20.31M | 9.74M | 3.31M | 3.09M |
| Cash & Equivalents | - | 695.91K | 27.74M | 15.31M | 2.34M | 1.88M | 6.88M |
| Long Term Debt | - | - | 3.42M | - | - | - | - |
| Total Liabilities | - | 22.31M | 5.93M | 4.31M | 6.08M | 6.04M | 6.44M |
| Current Liabilities | - | 22.14M | 2.51M | 4.28M | 6.05M | 5.77M | 6.23M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -288.38K | -10.67M | -5.82M | -5.81M | -8.26M | -4.24M |
| Investing Cash Flow | -1.10M | -1.04M | -3.19M | -7.23M | 1.98M | -1.00M |
| Financing Cash Flow | 2.03M | 38.75M | -3.42M | 70.89K | 5.82M | 10.24M |
| Capital Expenditure | -426 | -2.55K | -215.50K | -19.48K | -31.55K | -454 |
| Free Cash Flow | -288.81K | -10.67M | -6.03M | -5.83M | -8.30M | -4.24M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -29.4% | -53.2% | -97.9% | -112.5% | -137.0% | -465.4% |
| Net Margin % | -56.8% | -80.5% | -98.5% | -111.8% | -134.5% | -543.7% |
| ROE % | 17.1% | -30.1% | -50.4% | -113.9% | -377.5% | -339.6% |
| ROCE % | 15.1% | -17.8% | -50.1% | -114.3% | -355.6% | -272.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | 1.27% | 32.04K | $42.61K |
| 2 | Jane Street Group, LLC | 0.97% | 24.41K | $32.47K |
| 3 | IFP Advisors, Inc | 0.33% | 8.20K | $10.91K |
| 4 | Tower Research Capital LLC (TRC) | 0.01% | 219 | $291 |
| 5 | Blackrock Inc. | - | 71 | $94 |
| 6 | Caitong International Asset Management Co., Ltd | - | 2 | $2 |
| 7 | SBI Securities Co., Ltd. | - | 1 | $1 |
| 8 | Vanguard Capital Management LLC | - | 31 | $41 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ISPC
iSpecimen Completes Large-Scale International Cancer Research Order; Samples Shipped Within Three Weeks
Woburn, Massachusetts--(Newsfile Corp. - August 20, 2026) - iSpecimen, (NASDAQ: ISPC) a provider of human biospecimens, recently completed an international cancer research project involving hundreds of cancer blood specimens, with the sampl…
iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
WOBURN, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare sp…
E.F. Hutton & Co. Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, toda…
E.F. Hutton & Co. Acts as Acts as Exclusive Placement Agent for $5.0 Million Public Offering for iSpecimen
Transaction Marks E.F. Hutton's Third Capital Markets Engagement with iSpecimen Since December 2025NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, toda…
E.F. Hutton & Co. Serves as Exclusive Placement Agent on iSpecimen Inc. $2.5 Million Private Placement
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the exclusive placement agent in connection wit…
iSpecimen Announces 1-for-40 Reverse Stock Split
Woburn, Massachusetts--(Newsfile Corp. - April 24, 2026) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of hea…
ISPC — Frequently Asked Questions
What is the current share price of iSpecimen Inc. (ISPC)?
As of 2026-09-19 21:16 PDT, iSpecimen Inc. (ISPC) trades at $1.59 on NasdaqCM. Its 52-week range is $1.49 to $78.00.
What is the market capitalisation of ISPC?
iSpecimen Inc. (ISPC) has a market capitalisation of $4.00M on NasdaqCM.
What is the P/E ratio of ISPC?
ISPC trades at a trailing price-to-earnings (P/E) ratio of -0.03. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.17.
Is ISPC a good stock to buy?
This page provides a data-driven analysis of iSpecimen Inc. (ISPC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.